Orchestra BioMed Holdings, Inc. (OBIO)

Market Cap	109.57M
Revenue (ttm)	2.89M
Net Income (ttm)	-66.32M
Shares Out	38.31M
EPS (ttm)	-1.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68,006
Open	2.800
Previous Close	2.830
Day's Range	2.760 - 2.880
52-Week Range	2.370 - 8.870
Beta	0.66
Analysts	Strong Buy
Price Target	14.20 (+396.5%)
Earnings Date	May 12, 2025

About OBIO

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company’s flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 70
• Stock Exchange: NASDAQ
• Ticker Symbol: OBIO
• Website: https://orchestrabiomed.com

Financial Performance

In 2024, Orchestra BioMed Holdings's revenue was $2.64 million, a decrease of -4.42% compared to the previous year's $2.76 million. Losses were -$61.02 million, 24.2% more than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for OBIO stock is "Strong Buy." The 12-month stock price forecast is $14.2, which is an increase of 396.50% from the latest price.

Price Target

$14.2

(396.50% upside)

Analyst Consensus: Strong Buy